EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR A New Study Suggests Screen Time Might Not Be The Worst... November 14, 2019 Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... April 25, 2022 Sacituzumab Govitecan Improves Outcomes Over Single-Agent Chemotherapy in Patients with Pretreated... March 5, 2024 Spending Review 2020 – Steps in the right direction, but opportunities... November 25, 2020 Load more HOT NEWS The Caregiver Curve How Are Eligibility Criteria for Clinical Trials Changing to Help People... 10 Things About You That Change When You Lose Your Parents Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced...
